• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Malignant Glioma - Pipeline Review, H1 2013 - Product Image

Malignant Glioma - Pipeline Review, H1 2013

  • ID: 2557578
  • May 2013
  • 107 pages
  • Global Markets Direct

Malignant Glioma – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Malignant Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Malignant Glioma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Malignant Glioma.
- A review of the Malignant Glioma products under development by companies and universities/research institutes READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Malignant Glioma Overview
Therapeutics Development
An Overview of Pipeline Products for Malignant Glioma
Malignant Glioma Therapeutics under Development by Companies
Malignant Glioma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Malignant Glioma Therapeutics – Products under Development by Companies
Malignant Glioma Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Malignant Glioma Therapeutics Development
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
Eisai Co., Ltd.
Oncolytics Biotech Inc.
Cytomedix, Inc.
Nerviano Medical Sciences S.r.l.
BioNumerik Pharmaceuticals, Inc.
Biovista Inc.
EirGen Pharma Ltd.
Malignant Glioma – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
lenvatinib - Drug Profile
rilotumumab - Drug Profile
SAR-245409 - Drug Profile
pelareorep - Drug Profile
imatinib + [everolimus] + [hydroxyurea] - Drug Profile
milciclib - Drug Profile
afatinib - Drug Profile
XL-765 + [temozolomide] - Drug Profile
cositecan - Drug Profile
cositecan - Drug Profile
afatinib + [temozolomide] - Drug Profile
bortezomib + [bevacizumab] - Drug Profile
Dendritic Vaccine Pulsed With Multiple Peptides - Drug Profile
celecoxib + Dendritic Cell Vaccine + [temozolomide] + Radiation Therapy - Drug Profile
Dendritic Cells + [imiquimod] - Drug Profile
bevacizumab - Drug Profile
Pan-HLA Peptide Vaccine - Drug Profile
galunisertib - Drug Profile
Survivin Peptide Vaccine + [Montanide ISA-51] + [sargramostim] - Drug Profile
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen - Drug Profile
Dendritic Cell + Dendritic Cell Activated Cytokine Induced Killer Cell - Drug Profile
Autologous Dendritic Cell Tumor Vaccine - Drug Profile
AZD-7451 - Drug Profile
carmustine SR - Drug Profile
Eir-060 - Drug Profile
ALD-451 - Drug Profile
DNX-2401 - Drug Profile
BVA-501 - Drug Profile
BVA-701 - Drug Profile
Malignant Glioma Therapeutics – Drug Profile Updates
Malignant Glioma Therapeutics – Discontinued Products
Malignant Glioma Therapeutics - Dormant Products
Malignant Glioma – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Malignant Glioma, H1 2013
Products under Development for Malignant Glioma – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Development by Companies, H1 2013 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2013
Boehringer Ingelheim GmbH, H1 2013
F. Hoffmann-La Roche Ltd., H1 2013
Amgen Inc., H1 2013
Sanofi-Aventis, H1 2013
AstraZeneca PLC, H1 2013
Eisai Co., Ltd., H1 2013
Oncolytics Biotech Inc., H1 2013
Cytomedix, Inc., H1 2013
Nerviano Medical Sciences S.r.l., H1 2013
BioNumerik Pharmaceuticals, Inc., H1 2013
Biovista Inc., H1 2013
EirGen Pharma Ltd., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Malignant Glioma Therapeutics – Drug Profile Updates
Malignant Glioma Therapeutics – Discontinued Products
Malignant Glioma Therapeutics – Dormant Products
Malignant Glioma Therapeutics – Dormant Products (Contd..1)

List of Figures
Number of Products under Development for Malignant Glioma, H1 2013
Products under Development for Malignant Glioma – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 40

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos